NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03444766,Study of Nivolumab for Advanced Cancers in India,https://clinicaltrials.gov/study/NCT03444766,,COMPLETED,This is a study of nivolumab in participants with advanced Non-Small Cell Lung Cancer or Kidney Cancer in India.,YES,Non-Small Cell Lung Cancer (NSCLC)|Non-Small-Cell Lung Carcinoma|Nonsmall Cell Lung Cancer|Kidney Cancer|Kidney Neoplasms|Renal Cancer|Renal Neoplasms,DRUG: Nivolumab,"Number of Participants With Treatment-related Adverse Events, Number of participants with treatment-related Adverse Events based on worst ctc grade

Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest., 26 Weeks","Number of Participants With Treatment-related Select Adverse Events, Number of participants with treatment-related Select Adverse Events based on worst ctc grade for the following categories:

Pulmonary, Gastrointestinal, Endocrinopathies, Hepatic, Renal, Skin, Neurological and Hypersensitivity/Infusion reactions

Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest., 26 Weeks|Number of Participants With Treatment-related Serious Adverse Events, Number of participants with treatment-related Serious Adverse Events based on worst CTC grade

Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest., 26 Weeks|Number of Participants With Adverse Events Leading to Discontinuation, Number of participants with Adverse events leading to discontinuation of treatment based on worst CTC grade

Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest., 26 Weeks",,Bristol-Myers Squibb,,ALL,"ADULT, OLDER_ADULT",PHASE4,100,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,CA209-887,2018-03-06,2019-07-17,2019-07-17,2018-02-23,2020-10-16,2020-12-04,"Local Institution, Bangalore, 560027, India|Local Institution, Bangalore, 560072, India|Local Institution, Bengaluru, 560054, India|Local Institution, Hyderabad, 500034, India|Local Institution, Jaipur, 302004, India|Local Institution, Kolkata, 700156, India|Local Institution, Mumbai, 400012, India|Local Institution, New Delhi, 110029, India|Local Institution, Vellore, 632004, India","Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/66/NCT03444766/SAP_000.pdf|Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/66/NCT03444766/Prot_001.pdf"
